Colorectal Cancer

The CHMP recommended for approval nivolumab/ipilimumab for patients with MSI-H and dMMR unresectable or metastatic colorectal cancer.

The resubmission included an analysis of the phase 3 CARES-310 study, which reported favorable overall survival with the combination therapy in uHCC.

Data from the BLUE-C trial support the approval of the Cologuard Plus test for colorectal cancer screening among at-risk individuals.

Results from the INNATE trial showed the use of sotigalimab to be a safe and efficacious regimen for patients with rectal cancer.

The fixed-dose combination of favezelimab and pembrolizumab did not show an improvement in overall survival compared with the standard of care in patients with metastatic CRC.

The approval is based on results from the global phase 3 FRESCO-2 trial, which demonstrated improvement in OS in patients with refractory metastatic colorectal cancer.

NO-CUT trial data show that DRFS was maintained when non-operative management was used in patients with pMMR locally advanced rectal cancer.

Subgroup analysis in a phase 3 trial show OS benefits with the ramucirumab-based regimen in female patients and those with left-sided tumors.

Alessio Pigazzi, MD, PhD, FACS, FASCRS, provides advice for upcoming surgeons starting out in the colorectal cancer field.

Alessio Pigazzi, MD, PhD, FACS, FASCRS, discussed how robot-assisted surgery for colorectal cancers has evolved over the past 20 years.

Alessio Pigazzi, MD, PhD, FACS, FASCRS, discussed surgical and medical oncology developments in the colorectal cancer field.

Improved overall survival was also noted when atezolizumab plus bevacizumab and FOLFOXIRI were used to treat patients with pMMR tumors.

Panelists offer concluding perspectives on the future role of circulating tumor DNA in colorectal cancer management.

CytoDyn intends to submit its final study protocol to the FDA, engage a clinical research organization, and complete preparatory work to initiate the phase 2 trial.

Managing high-grade squamous intraepithelial lesions may reduce the risk of anal cancer based on data from the phase 3 ANCHOR trial.

Medical professionals analyze gaps in current colorectal cancer patient care, with a focus on minimal residual disease testing.

The panel examines challenges in interpreting circulating tumor DNA results and their impact on clinical decision-making processes.

Medical professionals explore methods for integrating circulating tumor DNA results with radiographic and pathologic findings to optimize patient care.

The panel examines a clinical scenario, detailing their approach to circulating tumor DNA testing, including turnaround times, and providing insights on patient counseling.

Shield, the first FDA-approved blood test for CRC screening, may offer convenient screening access for those who are at average risk for the disease.

Panelists analyze observed obstacles to implementing routine circulating tumor DNA testing as a standard of care, while offering strategies to overcome these challenges.

Panelists explore the clinical value of circulating tumor DNA testing at various stages of the colorectal cancer treatment journey, with a focus on optimal testing timelines.

The recommendation was made following mid-stage, end-of-phase 2 data for the botensilimab/balstilimab combination, which yielded lower responses in patients.

Key opinion leaders evaluate the selection of available assays and platforms in relation to specific clinical objectives.

Medical experts examine how recent data on circulating tumor DNA-based minimal residual disease testing may impact the clinical management and treatment of colorectal cancer.

Key opinion leaders analyze recent findings from the BESPOKE study.

The panel examines recent studies from the INTERCEPT program investigating the utility of circulating tumor DNA (ctDNA) for minimal residual disease (MRD) detection in colorectal cancer (CRC).

Jagoda Misniakiewicz, PharmD, discussed implementing fruquintinib into clinical practice and how it's mechanism of action compares with others in the space.

The key opinion leaders share their approaches for communicating about circulating tumor DNA and minimal residual disease to patients, emphasizing the significance of ctDNA testing in detecting MRD.

Experts outline circulating tumor (ct) DNA analysis, detailing the two main techniques and their respective advantages and disadvantages.